Method Article

An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons

DOI:

10.3791/61262

⸱

July 11th, 2020

 ,  ,  ,  , 
1Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, 2Department of Molecular and Cellular Biology, Faculty of Biological Sciences, Center for Aging and Regeneration (CARE UC), Pontificia Universidad Católica de Chile, 3Institute of Biomedical Sciences. Faculty of Medicine and Faculty of Life Sciences, Universidad Andrés Bello, 4Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and UK Dementia Research Institute at UCL, University College London Campus

In This Article

Summary

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Recombinant BDNF containing an Avi sequence (BDNFAvi) is produced in HEK293 cells in a cost-effective manner and is purified by affinity chromatography. BDNFavi is then directly mono-biotinylated with the enzyme BirA in a tube. BDNFavi and mono-biotinylated BDNFavi retain their biological activity when compared to commercially available BDNF.

Abstract

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Recombinant BDNF containing an Avi sequence (BDNFAvi) is produced in HEK293 cells and then cost-effectively purified by affinity chromatography. A reproducible protocol was developed to directly mono-biotinylate BDNFAvi with the enzyme BirA in a tube. In this reaction, mono-biotinylated BDNFAvi retains its biological activity.

Neurotrophins are target-derived growth factors playing a role in neuronal development and maintenance. They require rapid transport mechanisms along the endocytic pathway to allow long-distance signaling between different neuronal compartments. The development of molecular tools to study the trafficking of neurotrophins has enabled the precise tracking of these proteins in the cell using in vivo recording. In this protocol, we developed an optimized and cost-effective procedure for the production of mono-biotinylated BDNF. A recombinant BDNF variant containing a biotinylable avi sequence (BDNFAvi) is produced in HEK293 cells in the microgram range and then purified in an easily scalable procedure using affinity chromatography. The purified BDNF can then be homogeneously mono-biotinylated by a direct in vitro reaction with the enzyme BirA in a tube. The biological activity of the mono-biotinylated BDNF (mbtBDNF) can be conjugated to streptavidin-conjugated to different fluorophores. BDNFAvi and mbtBDNF retain their biological activity demonstrated through the detection of downstream phosphorylated targets using western blot and activation of the transcription factor CREB, respectively. Using streptavidin-quantum dots, we were able to visualize mbtBDNF internalization concomitant with activation of CREB, which was detected with a phospho-CREB specific antibody. In addition, mbtBDNF conjugated to streptavidin-quantum dots was suitable for retrograde transport analysis in cortical neurons grown in microfluidic chambers. Thus, in tube produced mbtBDNF is a reliable tool to study physiological signaling endosome dynamics and trafficking in neurons.

Introduction

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Neurons are the functional units of the nervous system possessing a complex and specialized morphology that allows synaptic communication, and thus, the generation of coordinated and complex behavior in response to diverse stimuli. Neuronal projections such as dendrites and axons are critical structural features involved in neuronal communication, and neurotrophins are crucial players in determining their morphology and function1. Neurotrophins are a family of secreted growth factors that include NGF, NT-3, NT-4, and brain-derived neurotrophic factor (BDNF)2. In the central nervous system (CNS), BDNF participates in diverse biological processes including neurotransmission, dendritic arborization, maturation of dendritic spines, long-term potentiation, among others3,4. Therefore, BDNF plays a critical role in regulating neuronal function.

Diverse cellular processes regulate BDNF dynamics and function. On the neuronal surface, BDNF binds the tropomyosin receptor kinase B (TrkB) and/or the p75 neurotrophin receptor (p75). BDNF-TrkB and BDNF-p75 complexes are endocytosed and sorted in different endocytic organelles5,6,7,8. Correct intracellular trafficking of the BDNF/TrkB complex is required for proper BDNF signaling in different neuronal circuits9,10,11. For this reason, a deep understanding of BDNF trafficking dynamics and its alterations found in pathophysiological processes is essential to understand BDNF signaling in health and disease. The development of novel and specific molecular tools to monitor this process will help to drive this field forward and allow a better grasp of the regulatory mechanisms involved.

There are several tools available for the study of BDNF trafficking in neurons. A commonly used methodology involves the transfection of recombinant BDNF tagged with fluorescent molecules such as green fluorescent protein (GFP) or the monomeric fluorescent red-shifted variant of GFP mCherry12,13. However, a major shortcoming of BDNF overexpression is that it eliminates the possibility of delivering known concentrations of this neurotrophin. Also, it may result in cellular toxicity, obscuring the interpretation of results14. An alternative strategy is the transfection of an epitope-tagged TrkB, such as Flag-TrkB. This methodology allows the study of TrkB internalization dynamics15, but it also involves transfection, which might result in altered TrkB function and cellular toxicity. To overcome these methodological hurdles, recombinant variants of NGF and BDNF containing an Avi sequence (BDNFAvi), which can be mono-biotinylated by the biotin-ligase enzyme BirA, were developed16,17. Biotinylated recombinant BDNF can be coupled to different streptavidin-bound tools, which include fluorophores, beads, paramagnetic nanoparticles among others for detection. In terms of live-cell imaging, quantum dots (QD) have become frequently used fluorophores, as they have desirable characteristics for single-particle tracking, such as increased brightness and resistance to photobleaching when compared to small molecule fluorophores18.

The production of mono-biotinylated BDNF (mbtBDNF) using BDNFAvi has been achieved by co-transfection of plasmids driving the expression of BDNFAvi and BirA, followed by the purification of the recombinant protein by affinity chromatography with a yield of 1-2 μg of BDNF per 20 mL of HEK293-conditioned culture media17. Here, we propose a modification of this protocol that allows for BDNFAvi purification from 500 mL of HEK293-conditioned media, which seeks to maximize protein recovery in a chromatography-column based protocol for ease of manipulation. The used transfection agent, polyethyleneimine (PEI), ensures a cost-effective method without sacrificing transfection yield. The mono-biotinylation step has been adapted to an in vitro reaction to avoid the complications associated with co-transfections and to ensure homogeneous labeling of BDNF. The biological activity of the mbtBDNF was demonstrated by western blot and fluorescence microscopy experiments, including activation of pCREB and live cell imaging to study retrograde axonal transport of BDNF in microfluidic chambers. The use of this protocol allows for optimized, high-yield production of homogenous mono-biotinylated and biologically active BDNF.

Access restricted. Please log in or start a trial to view this content.

Protocol

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

All experiments were carried out in accordance with the approved guidelines of CONICYT (Chilean National Commission for Scientific and Technological Research). The protocols used in this study were approved by the Biosecurity and Bioethical and Animal Welfare Committees of the Pontificia Universidad Católica de Chile. Experiments involving vertebrates were approved by the Bioethical and Animal Welfare Committee of the Pontificia Universidad Católica de Chile.

NOTE: The following protocol was designed to purify BDNFAvi from a total volume of 500 mL of conditioned medium produced in HEK293 cells. The amount of conditioned medium that is produced and processed to purify BDNFAvi can be up or downscaled as needed. However, further optimization may be necessary under these circumstances. The composition of the culture media and buffers used throughout the protocol can be found in supplementary materials. 

1. Production and purification of BDNFAvi from HEK293-conditioned media

  1. Transfection of HEK293 cells
    1. Grow HEK293 cells to 70% confluence in supplemented DMEM medium (10% bovine fetal serum, 1x glutamate supplement, 1x antibiotic/antimycotic) in 15 cm culture dishes at 37 ºC.
    2. Change the medium to transfection buffer.
    3. Prepare the PEI-DNA mixture for transfection. Use two different 15 mL conical tubes to dilute DNA and PEI 25 K, respectively. Dilute 20 μg of plasmid DNA in a final volume of 500 μL in one tube. Dilute 60 μg of linear PEI 25K in a final volume of 500 μL in the other tube. Incubate at room temperature for 5 min. 
    4. Carefully pipette the DNA solution into the PEI tube, mixing once by up-down motion. Incubate at room temperature for 25 min. 
    5. Drip 1 mL of the PEI-DNA mixture throughout each 15 cm dish. Incubate the cells with the PEI-DNA mixture for 3 h at 37 ºC.
    6. Change the medium to fresh incubation buffer. 
  2. Media collection and storage
    1. Collect the medium from all the dishes 48 h after the transfection of HEK293 cells. Prepare concentrated stocks of the solutions described in the “supernatant modification buffer” section of Supplemental File 1 and add them to the HEK293 supernatant to achieve the listed final concentrations.
      NOTE: Cells can be discarded or recovered for further analysis.
    2. Incubate the medium in ice for 15 min. 
    3. Aliquot the medium into centrifuge tubes.
    4. Centrifuge the medium at 10,000 x g for 45 min in a 4 °C centrifuge. This step allows the elimination of cell debris and dead cells suspended in the media. 
    5. Collect the supernatants, add BSA at a final concentration of 0.1%. and then store at -20 °C. The media can be aliquoted before freezing for faster thawing during the purification step.
      NOTE: Storage times of frozen conditioned media of up to 2 months have yielded positive results, longer storage times have not been evaluated.
  3. Media concentration and purification 
    1. Thaw the media in a 37 °C thermoregulated bath.
    2. Aliquot the media into centrifuge tubes. 
    3. Centrifuge the medium for 1 h at 3,500 x g in a 4 °C cooled centrifuge. This step allows the elimination of remaining cell debris to ensure adequate flow through the chromatography column.
    4. Use the protein concentrators with a 10 kDa cutoff to reduce the media from 500 mL to 100 mL. Follow the manufacturer’s recommended centrifugation parameters for optimal concentration.
    5. Add 500 μL of Ni-NTA agarose beads to the concentrated media and incubate overnight at 4 °C in a rocker. 
    6. Assemble the chromatography apparatus and pour the media into it. Let it rest for 5 min and then open the 2-way stopcock to let the medium flow through.
    7. Wash the beads with 5 mL of wash buffer for 5 min. Make sure to resuspend the beads in the column. Drain the wash buffer by opening the 2-way stopcock. Repeat 3 times.
    8. Add 1 mL of elution buffer to the column. Make sure to resuspend the beads in the column. Incubate for 15 min, and then collect the eluate in a 1.5 mL microcentrifuge tube. Repeat this step 3 times for complete elution of BDNFAvi.
    9. Load 5 μL of each eluate and different concentrations of commercially available BDNF (40-160 ng) in a 15% polyacrylamide gel. Detect the purified protein by western blotting using an anti-BDNF antibody. 
    10. Determine the concentration of the purified BDNFAvi in each eluate using the concentration curve prepared with the commercially available BDNF.
    11. Aliquot and store the purified BDNFAvi at -80 °C.

2. In vitro mono-biotinylation of BDNFAvi using the BirA enzyme

  1. In vitro mono-biotinylation reaction 
    1. Prepare concentrated stock solutions of the biotinylation buffer reagents. The use of concentrated stocks will minimize the dilution of the recombinant protein. 
    2. Take an aliquot of 800 ng of BDNFAvi and add the biotinylation buffer reagents and the enzyme BirA in a 1:1 molar relation to BDNF. For example, for a 200 μL final reaction volume add; 100 μL of solution containing 800 ng of BDNFAvi, 20 μL Bicine 0.5 M pH 8.3, 20 μL ATP 100 mM, 20 μL MgOAc 100 mM, 20 μL d-biotin 500 μM, 0.8-1 μg to 1 μL of BirA-GST, and complete to 200 μL with ultrapure water. 
      NOTE: Successful biotinylation reactions have been performed with aliquots of 400 μL containing a concentration of about 30 ng/ μL BDNFAvi, resulting in a homogeneously biotinylated BDNFAvi to a final concentration of ~20 ng/ μL in the final reaction.
    3. Incubate the mixture at 30 °C in a hybridization oven for 1 h. Mix the content by tube inversion every 15 min. 
    4. Add the same volume of ATP and BirA as in step 2.1.2 and repeat step 2.1.3. 
    5. Store at -80 °C for future analyses or keep on ice for immediate use (e.g., biotinylation quality control).
  2. Biotinylation analysis
    1. Block 30 μL of streptavidin magnetic beads per BDNF sample in 1 mL of blocking buffer. Incubate at room temperature for 1 h in a microcentrifuge tube rotator. 
    2. Precipitate the magnetic beads using a magnetic separation rack for 3 to 5 minutes or until the buffer appears completely cleared of the beads  and discard the blocking buffer.
    3. Add 50 μL of fresh blocking buffer and 80 ng of mono-biotinylated BDNFAvi (mbtBDNF) sample to the beads, making sure to resuspend them completely by pippeting.
    4. Incubate at 4 °C for 1 h in a microcentrifuge tube rotator  spinning at approximately 20 RPM. 
    5. Collect the beads using the magnetic separation rack for 3 to 5 minutes, and collect the supernatant, keeping a 30 μL aliquot for analysis.
    6. Wash the beads one time with 500 μL of PBS, and then collect them using the magnetic separation rack for 3 to 5 minutes. Recover the supernatant and keep a 30 μL aliquot for analysis. 
    7. Add 10 μL of 4x loading buffer to the beads.
    8. Heat the samples to 97 °C for 7 min to elute the mbtBDNF. 
    9. Detect mbtBDNF using an anti-BDNF specific antibody19.

3. Verification of mbtBDNF biological activity

  1. Detection of pTrkB and pERK by western blot.
    1. Seed 2 million rat cortical neurons in 60 mm culture dishes. 
    2. Culture the neurons for 7 days (DIV7). Then, change the medium to non-supplemented neurobasal mediun when starting the experiment.
    3. One hour after medium change, add mbtBDNF to a final concentration of 50 ng/mL. Incubate for 30 min at 37 ºC. Keep a negative control dish (non-stimulated with BDNF) and a positive control dish (treated with 50 ng/mL of commercially available BDNF).
    4. Collect the medium and gently wash every dish with 1x PBS. Collect and discard the 1x PBS.
    5. Place the dishes on ice and add 50-80 μL of lysis buffer to each dish. Use a cell scraper to lyse the cells. 
      NOTE: The lysis step should be performed as quickly as possible to avoid protein dephosphorylation and degradation. 1-2 minutes of vigorous scraping are enough to visualize the proteins of interest by western blotting. 
    6. Collect the lysis buffer and stir in a vortex mixer at highest speed for 5 s.
    7. Centrifuge the lysis buffer at 14,000 x g (4 °C) for 10 min. Collect the supernatant.
    8. Quantify the protein content of the supernatant  by BCA protein quantification protocol20.
    9. Add loading buffer to an aliquot containing 30-50 μg of protein per condition and load it in a 12% polyacrylamide gel for western blotting. Detect pTrkB and pERK using specific phospho-antibodies to verify BDNFAvi biological activity.
  2. Verification of BDNF-QD biological activity by pCREB immunofluorescence.
    1. Seed 40,000 rat cortical neurons in 10 mm coverslips, previously autoclaved and treated with poly-L-lysine as described previously21.
    2. Culture the neurons for 7-8 days in neuronal maintenance buffer (see supplemental materials) at 37 ºC. 
    3. To start the experiment, change the medium to unsupplemented neurobasal medium and incubate at 37 ºC for 1 h.
    4. Prepare mbtBDNF conjugated to quantum dots (BDNF-QD) by adding to a mbtBDNF aliquot, the necessary volume of quantum dot streptavidin conjugate (streptavidin-QD) to achieve a 1:1 BDNF-QD molar ratio. Then, dilute to 20 μL with neurobasal medium. Wrap the tube in aluminum foil to protect it from the light. 
      NOTE: Prepare another tube with the same volume of quantum dot streptavidin conjugate and dilute it to 20 μL with neurobasal medium as a negative control.
    5. Incubate the mbtBDNF/ streptavidin-QD mixture for 30 min at room temperature in a rocker. 
    6. Dilute the BDNF-QD to the desired final concentration (200 pM and 2 nM) in neurobasal medium.
    7. After 1 h of incubation with non-supplemented neurobasal medium, stimulate the neurons with BDNF-QD or streptavidin-QD (control) to a final concentration of 200 pM and 2 nM of BDNF for 30 min at 37 °C. 
    8. Wash the coverslips 3 times with 1x PBS (37 °C) and fix the cells for 15 min by treating the coverslip with 4% paraformaldehyde solution containing phosphatase inhibitors.
    9. Wash the cells 3 times with PBS, and then incubate with blocking/permeabilization buffer (BSA 5%, Triton X-100 0.5%, 1x phosphatase inhibitor) for 1 h.
    10. Incubate with anti-pCREB antibody 1:500 (in 3% BSA, 0.1% Triton X-100) overnight at 4 °C. 
    11. The following day, wash 3 times with 1x PBS, and incubate for 1 h with the secondary antibody 1:500 (3% BSA, 0.1% Triton X-100). 
    12. Wash 3 times with 1x PBS. Add Hoechst nuclear stain solution (5 μg/mL) for 7 min. 
    13. Wash 3 times with 1x PBS and mount.
  3. Visualization of retrograde axonal transport of BDNF-QD in live neurons
    1. Prepare microfluidic chambers and seed neurons as described previously16.
    2. After 7-8 days in culture, change the medium to non-supplemented neurobasal medium.
    3. Prepare mbtBDNF conjugated to quantum dots (BDNF-QD) by adding to a mbtBDNF aliquot, the necessary volume of quantum dot streptavidin conjugate (streptavidin-QD) to achieve a 1:1 BDNF-QD molar ratio. Then, dilute to 20 μL with neurobasal medium. Wrap the tube in aluminum foil to protect it from the light. 
      NOTE: Prepare another tube with the same volume of quantum dot streptavidin conjugate and dilute it to 20 μL with neurobasal medium as a control.
    4. Incubate the mbtBDNF/ streptavidin-QD mixture for 30 min at room temperature in a rocker. 
    5. Dilute the BDNF-QD to the desired final concentration (2 nM).
    6. After 1 h of incubation with non-supplemented neurobasal medium add the BDNF-QD or the control mixture to the axonal compartments of the microfluidic chamber. Incubate for 210 min at 37 ˚C to ensure a net retrograde transport of BDNF-QD.
    7. For live-cell imaging, visualize axonal retrograde transport in the segment of the microgrooves that is proximal to the cell body compartment using a 100x objective using a microscope suitable for these purpose (37 °C and 5% CO2). Acquire images at 1 frame/s. 

Access restricted. Please log in or start a trial to view this content.

Results

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The use of a chromatographic column-based protocol allows the processing of significant volumes of HEK293 conditioned media. In Figure 1, the results of the purification of BDNFAvi from 500 mL of conditioned media are shown. Consecutive elutions of BDNFAvi from the Ni-NTA agarose beads yield decreasing concentrations of BDNFAvi (Figure 1A). After four consecutive elutions (each lasting 15 min), the majority of the BDNF captured by the beads is recovered. The con...

Access restricted. Please log in or start a trial to view this content.

Discussion

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

In this article, an optimized methodology for the production and purification of mbtBDNF in an affinity chromatography-based procedure is described, based on the work of Sung and collaborators17. The optimizations include the use of a cost-effective transfection reagent (PEI) while maintaining the efficiency of more expensive transfection methods such as lipofectamine. This optimization translates into a significant cost reduction in the protocol, allowing for scalability while maintaining high co...

Access restricted. Please log in or start a trial to view this content.

Disclosures

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors have nothing to disclose.

Acknowledgements

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors gratefully acknowledge financial support from Fondecyt (1171137) (FCB), the Basal Center of Excellence in Science and Technology (AFB 170005) (FCB), Millenium-Nucleus (P07/011-F) (FCB), the Wellcome Trust Senior Investigator Award (107116/Z/15/Z) (GS) and a UK Dementia Research Institute Foundation award (GS). This work was supported by the Unidad de Microscopía Avanzada UC (UMA UC).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
2 way stopcockBioRad7328102Chromatography apparatus component
2-mercaptoethanolSigmaM6250BDNF elution buffer
Acrylamide/BisacrylamideBioRad1610154SDS-PAGE gel preparation
Amicon Ultra-15 10KMilliporeUFC901024BDNF concentration
Ammonium PersulfateSigmaA9164SDS-PAGE gel preparation
anti B-III-Tubulin antibodySigmaT8578Western blot assays for BDNF biological activity detection
anti BDNF antibodyAlomoneAGP-021Western blot assays for BDNF quantification
anti BDNF antibodyAlomoneANT-010Western blot assays for BDNF quantification
Anti ERK antibodyCell Signaling9102Western blot assays for BDNF biological activity detection
anti pCREB antibody (S133)Cell Signaling9198Western blot assays for BDNF biological activity detection
anti pERK antibody (T202, Y204)Cell Signaling4370Western blot assays for BDNF biological activity detection
anti pTrkB antibody (Y515)Abcamab109684Western blot assays for BDNF biological activity detection
Antibiotic/AntimycoticGibco15240-062HEK293 maintenance
ATPSigmaA26209BDNF monobiotinylation buffer
B-27 SupplementGibco17504-044Neuron maintenance
BicineSigmaB3876BDNF monobiotinylation buffer
BirA-GSTBPS Bioscience70031Enzyme for BDNF AviTag monobiotinylation
Bovine Fetal SerumHyCloneHC.SH30396.02HEK293 maintenance
Bovine Serum AlbuminJackson ImmunoResearch001-000-162BDNF buffer modification component, blocking buffer for western blot and immunofluorescence
D-BiotinSigmaB4639BDNF monobiotinylation buffer
DMEM High Glucose MediumGibco11965-092Neuron seeding
DMEM MediumGibco11995-081HEK293 maintenance
Econo Column FunnelBioRad7310003Chromatography apparatus component
EDTAMerck108418
EZ-ECL KitBiological Industries1633664Protein detection by western blotting
GlutamaxGibco35050-061Neuron and HEK293 maintenance
GlycerolMerck104094BDNF elution buffer, lysis buffer for western blot assays
Hettich Rotina 46R CentrifugeHettichDiscontinuedCentrifuge used for clearing the medium of debris
Hettich Universal 32R CentrifugeHettichDiscontinuedCentrifuge used for protein concentrator centrifugation
Horse SerumGibco16050-122Neuron seeding
ImageQuant LAS 500GE Healthcare Life Sciences29005063Western blot image acquisition
ImidazoleSigmaI55513BDNF buffer modification component
KClWinklerBM-1370PBS component
KH2PO4Merck104873PBS component
LamininInvitrogen23017-015Cover coating for compartmentalized neurons
Luer Tubing AdaptorBioRad7323245Chromatography apparatus component
Luminata™ Forte Western HRP SubstrateMilliporeWBLUF0100Protein detection by western blotting
Mg(CH3COO)2Merck105819BDNF monobiotinylation buffer
Mowiol 4-88Calbiochem475904Mounting reagent for immunofluorescence assays
MyOne C1 Streptavidin Magnetic BeadsInvitrogen65001Biotinylation verification
Na2HPO4Merck106586BDNF buffer modification component
NaClWinklerBM-1630PBS component, BDNF buffer modification component
NaH2PO4Merck106346BDNF buffer modification component
Neurobasal MediumGibco21103-049Neuron maintenance
Ni-NTA Agarose BeadsQiagen30210BDNF AviTag purification
Nikon Ti2-ENikonMicroscope for fluorescence imaging
Nitrocellulose MembraneBioRad1620115Protein transfer for western blotting
ORCA-Flash4.0 V3 Digital CMOS cameraHamamatsuC13440-20CUCamera for epifluorescence imaging
P8340 Protease Inhibitor CocktailSigmaP8340BDNF buffer modification component
ParaformaldehydeMerck104005Fixative for immunofluorescence assays
Penicillin/StreptomycinGibco15140-122Neuron maintenance
Poli-D-LysineCorningDLW354210Cover coating for compartmentalized neurons
Poli-L-LysineMilliporeP2363Cover coating for non-compartmentalized neurons
Poly-Prep Chromatography ColumnBioRad7311550Chromatography apparatus component
Polyethyleneimine 25KPolysciences Inc.PLY-0296HEK293 transfection
Quantum Dots 655 streptavidin conjugateInvitrogenQ10121MPMonobiotinylated BDNF AviTag label for live and fixed cell experiments
SaponinSigmaS4521Detergent for immunofluorescence assays
Syldgard 184 silicone elastomer basePoirot4019862Microfluidic chamber preparation
TEMEDSigmaT9281SDS-PAGE gel preparation
TrisWinklerBM-2000Lysis buffer component
Triton X100Merck108603Cell permeabilization in immunofluorescence and western blot assays
Trypsin-EDTA 0.5%Gibco15400-054HEK293 passaging

References

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Huang, E., Reichardt, L. Neurotrophins: Roles in Neuronal Development and Function. Annual Review of Neuroscience. 24, 677-736 (2001).
  2. Skaper, S. D. The neurotrophin family of neurotrophic factors: an overview. Methods in Mollecular Biology. 846, 1-12 (2012).
  3. Gonzalez, A., Moya-Alvarado, G., Gonzalez-Billault, C., Bronfman, F. C. Cellular and molecular mechanism regulating neuronal growth by brain-derived neurotrophic factor. Cytoskeleton. 73 (10), 612-628 (2016).
  4. Cunha, C., Brambilla, R., Thomas, K. A simple role for BDNF in learning and memory. Frontiers in Mollecular Neuroscience. 3, 1(2010).
  5. Bronfman, F. C., Lazo, O. M., Flores, C., Escudero, C. A. Spatiotemporal intracelular dynamics of neurotrophin and its receptors. Implications for neurotrophin signaling and neuronal function. Neurotrophic Factor. Handbook of Experimental Pharmacology. Lewin, G., Carter, B. 220, Springer. Berlin, Heidelberg. (2014).
  6. Ascano, M., Bodmer, D., Kuruvilla, R. Endocytic trafficking of neurotrophins in neural development. Trends in Cell Biology. 22 (5), 266-273 (2012).
  7. Deinhardt, K., Salinas, S., Verastegui, C., Watson, R., Worth, D., Hanrahan, S., Bucci, C., Schiavo, G. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron. 52 (2), 293(2006).
  8. Escudero, C. A., et al. c-Jun N-terminal kinase (JNK)-dependent internalization and Rab5-dependent endocytic sorting medaited long-distance retrograde neuronal death induced by axonal BDNF-p75 signaling. Scientific Reports. 9, 6070(2019).
  9. Vrabec, J. P., Levin, L. A. The neurobiology of cell death in glaucoma. Eye. 21, Suppl 1 11-14 (2007).
  10. Liot, G., Zala, D., Pla, P., Mottet, G., Piel, M., Saudou, F. Mutant huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. Journal of Neuroscience. 33 (15), 6298-6309 (2013).
  11. Zhou, B., Cai, Q., Xie, Y., Sheng, Z. H. Snapin recruits dynein to BDNF-TrkB signaling endosomes for retrograde axonal transport and is essential for dendrite growth of cortical neurons. Cell Reports. 2 (1), 42-51 (2012).
  12. Haubensak, W., Narz, F., Heumann, R., Lessmann, V. BDNF-GFP containing secretory granules are localized in the vicinity of synaptic junctions of cultured cortical neurons. Journal of Cell Science. 111 (11), 1483-1493 (1998).
  13. Adachi, N., et al. Glucocorticoid affects dendritic transport of BDNF-containing vesicles. Scientific Reports. 5, 12684(2015).
  14. Biocompare: The Buyer's Guide for Life Scientists. Mirus Bio. Cellular Toxicity Caused by Transfection: Why is it important. , Available from: https://www.biocompare.com/Bench-Tips/121111-Cellular-Toxicity-Caused-by-Transfection-Why-is-it-important/ (2012).
  15. Zhao, L., et al. Mechanism underlying activity-dependent insertion of TrkB into the neuronal surface. Journal of Cell Science. 122 (17), 3123-3136 (2009).
  16. Zhao, X., Zhou, Y., Weissmiller, A., Pearn, M., Mobley, W., Wu, C. Real-time imaging of axonal transport of quantum dot-labeled BDNF in primary neurons. Journal of Visualized Experiments. 91, 51899(2014).
  17. Sung, K., Maloney, M., Yang, J., Wu, C. A novel method for producing mono-biotinylated, biologically active neurotrophic factors: an essential reagent for single molecule study of axonal transport. Journal of Neuroscience Methods. 200 (2), 121-128 (2011).
  18. Deerinck, T. The application of fluorescent quantum dots to confocal, multiphoton and electron microscopic imaging. Toxicologic Pathology. 36 (1), 112-116 (2008).
  19. Unsain, N., Nuñez, N., Anastasia, A., Mascó, D. H. Status epilepticus induces a TrkB to p75 neurotrophin receptor switch and increases brain-derived neurotrophic factor interaction with p75 neurotrophon receptor: an initial event in neuronal injury induction. Neuroscience. 154 (3), 978-993 (2008).
  20. Walker, J. M. The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol. 32, 5-8 (1994).
  21. Moya-Alvarado, G., Gonzalez, A., Stuardo, N., Bronfman, F. C. Brain-derived neurotrophic factor (BDNF) regulates Rab5-positive early endosomes in hippocampal neurons to induce dendritic branching. Frontiers in Cellular Neuroscience. 12, 493(2018).
  22. Sasi, M., Vignoli, B., Canossa, M., Blum, R. Neurobiology of local and intercellular BDNF signaling. Pflugers Archiv European Journal of Physiology. 469 (5), 593-610 (2017).
  23. Gonzalez, A., Lazo, O. M., Bronfman, F. C. The Rab5-Rab11 endosomal pathway is required for BDNF-induced CREB transcriptional regulation in neurons. , Available from: https://www.biorxiv.org/content/10.1101/844720v1 (2019).
  24. Mowla,, et al. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. Journal of Biological Chemistry. 276 (16), 12660-12666 (2001).
  25. Longo, P., Kavran, J., Kim, M. S., Leahy, D. Transient Mammalian Cell Transfection with Polyethyleneimine (PEI). Methods in Enzymology. 529, 227-240 (2013).
  26. Raymond, C., Tom, R., Perret, S., Moussouami, P., L'Abbé, D., St-Laurent, G., Durocher, Y. A simplified polyethyleneimine-mediated transfection process for large-scale and high-throughput applications. Methods. 55 (1), 44-51 (2011).
  27. Dalton, A., Barton, W. Over-expression of secreted proteins from mammalian cell lines. Protein Science. 23 (5), 517-525 (2014).
  28. Hunter, M., Yuan, P., Vavilala, D., Fox, M. Optimization of protein expression in mammalian cells. Current Protocols in Protein Science. 95 (1), 77(2019).
  29. Stepanenko, A. A., Heng, H. H. Transient and stable vector transfection: Pitfalls, off-target effects, artifacts. Mutation Research. 773, 91-103 (2017).
  30. Guerzoni, L. P., Nicolas, V., Angelova, A. In vitro modulation of TrkB receptor signaling upon sequential delivery of curcumin-DHA loaded carriers towards promoting neuronal survival. Pharmaceutical Research. 34 (2), 492-505 (2017).
  31. Angelova, A., Angelov, B. Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair. Neural Regeneration Research. 12 (6), 886-889 (2017).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

BDNF PurificationAffinity ChromatographyMono biotinylationBDNF OviductHEK293 CellsBirA EnzymeStreptavidin Quantum DotsCortical NeuronsMicrofluidic ChambersWestern Blot

Related Articles